<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">
LSX-Blog.png

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Addex prepares PD-LID programme for 2019 Phase 3 r...

Key findings: Switzerland-based Addex Therapeutics is preparing its lead ca...

Read More

World-first accreditation to out-of-this-world app...

Key learnings: Oxford-based Oxehealth has secured medical device accreditat...

Read More

Investorview: Propelling life science innovation f...

Denmark’s Novo Seeds was established in 2007 in order to identify promising...

Read More

Gates Foundation funding for DelSiTech’s silica-ba...

Key learnings: DelSiTech has been awarded significant grant funding from th...

Read More

€79m Series C pushes Galecto Biotech’s pipeline in...

Key learnings: Ysios Capital and OrbiMed led Galecto Biotech’s €79 million ...

Read More

Dyadic International: Working to change the game i...

Key learnings:

Read More

What life sciences companies need to know about pr...

Pre-approval access is evolving at a rapid pace. Mark Corbett (pictured), E...

Read More

Forendo Pharma receives €4m boost to progress wome...

Key learnings: Vesalius BioCapital III Partners invested €4 million in Finl...

Read More

Commercialise and partner successfully in Europe a...

Understand how to commercialise via partnering in Europe and other markets ...

Read More

Brexit: finite uncertainty

One might think that planning for uncertainty is something that biotech fir...

Read More

In a new age of personalised cancer therapy, is pa...

On 5 September 2018 it was announced that the NHS has struck a deal with No...

Read More

Make Brexit a non-issue for pharma

What is the recipe for keeping business momentum in clinical trials despite...

Read More

Add Your Response